{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=1&page=53",
    "query": {
      "intervention": "1",
      "page": 53
    },
    "page_size": 10
  },
  "pagination": {
    "page": 53,
    "page_size": 10,
    "total_count": 85838,
    "total_pages": 8584,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=1&page=54&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=1&page=52&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-03T00:05:54.386Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02950480",
      "title": "Breast Capsular Contracture Following Post-Mastectomy Reconstruction in Women Treated With the Leukotriene Inhibitor Zafirlukast: A Phase II Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "zafirlukast",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care (no intervention)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 89 Years · Female only"
      },
      "enrollment_count": 4,
      "start_date": "2017-03-13",
      "completion_date": "2018-12-20",
      "has_results": true,
      "last_update_posted_date": "2019-10-01",
      "last_synced_at": "2026-11-03T00:05:54.386Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02950480"
    },
    {
      "nct_id": "NCT05771480",
      "title": "Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Biliary Tract Cancer"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gemcitabine monotherapy",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine + cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine + oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine + carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine + cisplatin + S-1",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine + S-1",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine + cisplatin + albumin-bound paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 142,
      "start_date": "2023-08-16",
      "completion_date": "2026-09-17",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-11-03T00:05:54.386Z",
      "location_count": 4,
      "location_summary": "Mobile, Alabama • Orange, California • Washington D.C., District of Columbia + 1 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05771480"
    },
    {
      "nct_id": "NCT03317496",
      "title": "Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Urothelial Cancer"
      ],
      "interventions": [
        {
          "name": "Avelumab 800 mg in combination with pemetrexed / carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Avelumab 800 mg in combination with gemcitabine / cisplatin.",
          "type": "DRUG"
        },
        {
          "name": "Avelumab 1200 mg in combination with pemetrexed/carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Avelumab 1200 mg in combination with gemcitabine/cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2017-12-21",
      "completion_date": "2022-12-20",
      "has_results": true,
      "last_update_posted_date": "2023-08-29",
      "last_synced_at": "2026-11-03T00:05:54.386Z",
      "location_count": 8,
      "location_summary": "Tucson, Arizona • Stony Brook, New York • The Bronx, New York + 1 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03317496"
    },
    {
      "nct_id": "NCT01611662",
      "title": "Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Distal Urethral Cancer",
        "Proximal Urethral Cancer",
        "Squamous Cell Carcinoma of the Bladder",
        "Stage II Bladder Cancer",
        "Stage III Bladder Cancer",
        "Urethral Cancer Associated With Invasive Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "therapeutic conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2012-05-29",
      "completion_date": "2019-01-22",
      "has_results": true,
      "last_update_posted_date": "2019-07-29",
      "last_synced_at": "2026-11-03T00:05:54.386Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01611662"
    },
    {
      "nct_id": "NCT00907946",
      "title": "Comparing Previously Placed Nephrostomy Tract (NT) Versus Single Stage Percutaneous Nephrolithotomy (PCNL)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Urolithiasis"
      ],
      "interventions": [
        {
          "name": "NT 1 day before PCNL",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 8,
      "start_date": "2009-12",
      "completion_date": "2010-10",
      "has_results": false,
      "last_update_posted_date": "2019-01-11",
      "last_synced_at": "2026-11-03T00:05:54.386Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00907946"
    },
    {
      "nct_id": "NCT01014546",
      "title": "Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Essential Thrombocythemia",
        "Polycythemia Vera",
        "Primary Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Arsenic Trioxide",
          "type": "DRUG"
        },
        {
          "name": "Ascorbic Acid",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2010-04",
      "completion_date": "2015-02",
      "has_results": false,
      "last_update_posted_date": "2022-07-22",
      "last_synced_at": "2026-11-03T00:05:54.386Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01014546"
    },
    {
      "nct_id": "NCT01442688",
      "title": "Amoxicillin Drug Interaction Study With MMX® Mesalazine/Mesalamine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Amoxicillin + MMX placebo",
          "type": "DRUG"
        },
        {
          "name": "Amoxicillin + MMX mesalazine/mesalamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 62,
      "start_date": "2011-10-07",
      "completion_date": "2011-11-20",
      "has_results": true,
      "last_update_posted_date": "2021-06-09",
      "last_synced_at": "2026-11-03T00:05:54.386Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01442688"
    },
    {
      "nct_id": "NCT00265603",
      "title": "Safety Study: Combined Modality Treatment for Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Extracorporeal Photochemotherapy With Transimmunization",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Atlantic Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2004-10",
      "completion_date": "2009-04",
      "has_results": false,
      "last_update_posted_date": "2014-01-16",
      "last_synced_at": "2026-11-03T00:05:54.386Z",
      "location_count": 1,
      "location_summary": "Morristown, New Jersey",
      "locations": [
        {
          "city": "Morristown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00265603"
    },
    {
      "nct_id": "NCT00708903",
      "title": "Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "neratinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Puma Biotechnology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 60,
      "start_date": "2008-05",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2012-05-14",
      "last_synced_at": "2026-11-03T00:05:54.386Z",
      "location_count": 1,
      "location_summary": "Tacoma, Washington",
      "locations": [
        {
          "city": "Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00708903"
    },
    {
      "nct_id": "NCT00025727",
      "title": "Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Lopinavir/Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "GW433908",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 330,
      "start_date": "2001-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-11-03T00:05:54.386Z",
      "location_count": 32,
      "location_summary": "Phoenix, Arizona • Long Beach, California • Los Angeles, California + 25 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00025727"
    }
  ]
}